
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
Boehringer Ingelheim collaborates with Envisagenics to target cancer-specific RNA alterations in solid tumors using AI-centered technology.
Open originalFocused on biotech AI, AI in science, medicine, drug discovery, genetics, and biomedical research
Signals
Current biotech AI signals — AI in medicine, science, research, agents, and models.

Boehringer Ingelheim collaborates with Envisagenics to target cancer-specific RNA alterations in solid tumors using AI-centered technology.
Open original
This patient-specific method, called xvr, helps doctors use X-rays for surgical navigation in fields such as orthopedics and neurosurgery.
Open original
The handheld catheterization device AI-GUIDE promises improved health outcomes for injured individuals.
Open original
AI is changing the research process, enabling scientists to prioritize experiments more effectively and efficiently.
Open original
The Laboratory of Evolutionary Design is releasing Proto, a framework that integrates AI tools for biological design, aiming to accelerate the process of assembling natural components in biological research.
Open original
AI scientists are emerging as a new interface for scientific computing, according to NVIDIA BioNeMo.
Open original